Publique en esta revista
Información de la revista
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Scientific Letter
DOI: 10.1016/j.medine.2020.09.003
Acceso a texto completo
Disponible online el 4 de Octubre de 2020
Viral detection and serological response in critically ill patients with SARS-CoV-2. Implications for isolation withdrawal
Detección viral y respuesta serológica en pacientes críticos intubados con SARS-CoV-2. Implicaciones para retirada de aislamiento
Visitas
...
J.L. García Garmendiaa,
Autor para correspondencia
joseluis.garciagarmendia@sjd.es

Corresponding author.
, M. Ramírez Arcosb, A.E. Barrero Almodóvara, M. Chávez Caballerob, V. Jorge Amigoa, M.C. Serrano Martinob
a Unidad de Cuidados Intensivos, Servicio de Cuidados Críticos y Urgencias, Hospital San Juan de Dios del Aljarafe, Bormujos, Sevilla, Spain
b Unidad de Microbiología, Servicio de Laboratorio, Hospital San Juan de Dios del Aljarafe, Bormujos, Sevilla, Spain
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (1)
Table 1. Characteristics and diagnostic tests of the critical patients with SARS-CoV-2 infection subjected to mechanical ventilation.
Texto completo
Sir,

An outbreak produced by a new coronavirus in the Chinese province of Wuhan was declared in December 2019.1 The disease caused by this virus (SARS-CoV-2) is known as COVID-19, and the resulting pandemic has placed a heavy burden upon Intensive Care Units (ICUs), with many critically ill patients.2 The diagnosis is established from the detection of viral RNA in nasopharyngeal smears or bronchoalveolar lavage (BAL) samples.3 The host immune response in turn is established from blood IgM and IgG determinations using rapid qualitative tests.

In the clinically less severe cases, viral RNA detection is maximum during the first two weeks from symptoms onset,4 and after 7–10 days an IgM and subsequent IgG immune response is observed.5 However, in the more seriously ill patients, or in individuals with a prolonged course of the disease, increased persistence of the virus has been reported, to after 21 days from symptoms onset.4,6 In these cases characterized by a prolonged course, increased persistence of the IgM titers has moreover also been observed.5 The implications of all this in relation to patient isolation withdrawal are very important.7 The United States Centers for Disease Control (CDC) proposes as a safe strategy the determination of two consecutively negative rRT-PCR (real time reverse-transcription polymerase chain reaction) tests for assessing the need for isolating individuals with COVID-19.8

We present a retrospective descriptive analysis of the records of 10 intubated critical patients with SARS-CoV-2 infection admitted to the ICU of a district hospital and subjected to mechanical ventilation for over a week. Permission was obtained from the patients or their families for data collection. Critically ill patients were regarded as those presenting critical hypoxemia (paO2/FiO2< 100 for over 12 h) in the first 5 days, renal failure requiring extrarenal replacement therapy, or the need for norepinephrine at doses > 1 μg/kg/min.

These patients were subjected to two coronavirus rRT-PCR tests spaced 24 h apart from 21 days after symptoms in order onset to assess persistent viral elimination. In the positive cases, the two tests were repeated on a weekly basis. At the same time we evaluated patient serological status based on the serum coronavirus IgM and IgG titers. Isolation was withdrawn in the negative cases, with monitoring of the professionals and relatives that had been in contact with the patient.

In our setting, in the presence of high circulating virus levels, we apply a screening algorithm with the detection of coronavirus envelope gene (E) as the parameter defining SARS-CoV-2 infection.9 The rRT-PCR amplification test (TIB Molbiol, Roche®) was performed in nasopharyngeal exudates or BAL samples, using the under 40 cycle as positivity criterion.10,11 The qualitative detection of IgG/IgM antibodies against SARS-CoV-2 was carried out using a solid phase immunochromatographic assay in whole blood, serum or plasma (Zhejiang Orient Gene Biotech Co., Ltd). In comparison with rRT-PCR, this assay has a sensitivity of 87.9% and 97.2% for IgM and IgG, respectively, and a combined specificity of 100%.

Table 1 describes the analyzed patients, who presented a mean (± standard deviation [SD]) APACHE II score of 18.1 ± 5.8 after 24 h, and a mean SOFA score of 7.4 ± 1.6 after 72 h. Males predominated in a proportion of 4:1. The mean duration of the clinical condition at the time of rRT-PCR was 24 ± 3.6 days, the mean ICU stay at that time was 16.3 ± 3.5 days, and the mean duration of mechanical ventilation was 12.9 ± 3.1 days.

Table 1.

Characteristics and diagnostic tests of the critical patients with SARS-CoV-2 infection subjected to mechanical ventilation.

Case  Clinical conditiona  AP II  SOFA  PAFI < 100 > 12 h  ERRT  NE > 1  Days disease  Days MV  rRT-PCR 21 drRT-PCR 28 drRT-PCR 35 dIgG  IgM 
                  1st  2nd  1st  2nd  1st  2nd     
F 58  Extreme  13  Yes  No  No  21  10  −  −  NP  NP  NP  NP  ++  ++ 
M 64  Extreme  24  Yes  Yes  Yes  22  12  NP  −  −  −  ++  ++ 
F 69  Very severe  12  No  No  No  22  12  −  −  −  NP  NP  ++ 
M 76  Very severe  23  No  No  No  21  −  −  NP  NP  NP  NP  ++ 
M 76  Very severe  18  No  No  No  31  12  −  −  NP  NP  NP  NP  ++ 
M 71  Very severe  13  No  No  No  22  13  −  −  NP  NP  NP  NP  ++  ++ 
M 56  Very severe  10  No  No  No  25  12  −  −  NP  NP  NP  NP  ++ 
M 48  Very severe  19  No  No  No  21  15  −  −  NP  NP  NP  NP  ++  ++ 
M 76  Very severe  26  No  No  No  29  19  −  −  NP  NP  NP  NP  ++  ++ 
M 70  Extreme  23  10  Yes  No  Yes  26  16  NP  NP  −  −  ++  ++ 

AP II: APACHE II (Acute Physiology, Age, Chronic Health Evaluation) score after 24 h; d: days; M: male; IgG: immunoglobulin G; IgM: immunoglobulin F; NE > 1: norepinephrine at dose > 1 μg/kg/min; F: female; NP: not performed; PAFI: paO2/FiO2; rRT-PCR: real time reverse-transcription polymerase chain reaction for coronavirus RNA; SOFA: Sequential Organ Failure Assessment score after 72 h; ERRT: extrarenal replacement therapy; MV: mechanical ventilation.

a

Extreme severity if paO2/FiO2 > 12 h or requiring extrarenal replacement therapy or needing norepinephrine at dose > 1 μg/kg/min during the first 5 days of UCI stay.

In three cases (30%; 95% confidence interval [95%CI]: 7–65%), viral RNA was detected in one of the samples after the 21 day period. One patient presented a first negative test followed by a positive test. In the rest of the cases both tests proved negative (Fig. 1). With regard to the severity of the condition, two of the three extremely severe cases showed persistent viral RNA detection, versus one of the 7 very severe cases (p = 0.18). Of the three patients with positive rRT-PCR, two of them continued to present detectable viral RNA levels in at least one sample after one week. These two cases experienced negative conversion in the following week. All the patients developed an immune response as evaluated by the antibody titers, and none showed negative conversion of IgM on day 21 – though the IgM response was qualitatively lower in four of the 7 very severe cases, versus in none of the extremely severe cases (p = 0.20). Isolation withdrawal was decided in the negative cases, and after a mean follow-up of 13.5 ± 2.6 days, no symptoms were detected in either the families or the supervising professionals, and no positive PCR tests were recorded in any professional of the hospital.

Figure 1.

Monitoring of coronavirus rRT-PCR negative conversion in 10 critical patients with SARS-CoV-2 infection subjected to mechanical ventilation. *One patient with a first negative rRT-PCR test and a second positive test.

(0,17MB).

The detection of viral RNA using rRT-PCR appears to be adequate for evaluating the need for isolating patients with SARS-CoV-2 infection.8,12 This has implications in relation to work load, the use of protective equipment and care, and moreover influences the patient mood state and facilitates reassignment of the patients in other areas.

Doubts remain as to whether the detection of viral RNA in late phases corresponds to truly infective viruses or to viral RNA fragments unable to generate new disease.12 Nevertheless, it seems reasonable to require two negative samples to confirm non-infectivity, taking into account the possibility of false-negative readings, as evidenced in two of our cases. The correlation between patient serological response and effective infection control is not clear. The persistence of IgM titers, perhaps more so in the more seriously ill cases, could be related to the intensity of presentation.

The limitations of this study are its limited sample size; the fact that rRT-PCR determination of an envelope gene common to other coronaviruses was used (despite being validated in high circulation situations); and the use of qualitative antibody testing.

In sum, latent infectivity in critical patients with SARS-CoV-2 after 21 days of disease has not been sufficiently established. Persistent viral RNA levels are evidenced beyond four weeks in the more seriously ill cases. The confirmation of two consecutively negative rRT-PCR tests and the detection of IgG antibody titers could be regarded as a valid strategy in deciding patient isolation withdrawal.

References
[1]
N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al.
A novel coronavirus from patients with pneumonia in China, 2019.
N Engl J Med, 382 (2020), pp. 727-733
[2]
X. Yang, Y. Yu, J. Xu, H. Shu, J. Xia, H. Liu, et al.
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
[3]
L. Guo, L. Ren, S. Yang, M. Xiao, Chang, F. Yang, et al.
Profiling early humoral response to diagnose novel coronavirus disease (COVID-19).
Clin Infect Dis, (2020),
[4]
Y. Liu, L.M. Yan, L. Wan, T.X. Xiang, A. Le, J.M. Liu, et al.
Viral dynamics in mild and severe cases of COVID-19.
[5]
W. Liu, L. Liu, G. Kou, Y. Zheng, Y. Ding, W. Ni, et al.
Evaluation of nucleocapsid and spike protein-based ELISAs for detecting antibodies against SARS-CoV-2.
J Clin Microbiol, (2020),
[6]
K.K. To, O.T. Tsang, W.S. Leung, A.R. Tam, T.C. Wu, D.C. Lung, et al.
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
[7]
P. Rascado Sedes, M.A. Ballesteros Sanz, M.A. Bodí Saera, L.F. Carrasco Rodríguez-Rey, A. Castellanos Ortega, M. Catalán González, et al.
Junta directiva de la SEMICYUC, Junta directiva de la SEEIUC. Plan de contingencia para los servicios de medicina intensiva frente a la pandemia COVID-19.
[8]
Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance), Center for Disease Control and Prevention, (2020),
[9]
WHO/COVID-19/laboratory/2020.5 Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases 2020.
[10]
Y. Liu, Y. Lui, B. Diao, F. Ren, Y. Wang, J. Ding, et al.
Diagnostic indexes of a rapid IgG/IgM combined antibody test for SARS-CoV-2.
[11]
V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, et al.
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
[12]
L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, et al.
SARS-CoV-2 viral load in upper respiratory specimens of infected patients.
N Engl J Med, 382 (2020), pp. 1177-1179

Please cite this article as: García Garmendia JL, Ramírez Arcos M, Barrero Almodóvar AE, Chávez Caballero M, Jorge Amigo V, Serrano Martino MC. Detección viral y respuesta serológica en pacientes críticos intubados con SARS-CoV-2. Implicaciones para retirada de aislamiento. Med Intensiva. 2020. https://doi.org/10.1016/j.medine.2020.09.003

Copyright © 2020. Elsevier España, S.L.U. and SEMICYUC
Idiomas
Medicina Intensiva

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.